This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ZDH | |
|---|---|
| Name | ZDH |
| Organism | Human |
ZDH
ZDH is a protein-coding entity referenced in molecular biology literature and clinical genetics contexts. It is discussed in connection with proteins, genes, and pathways studied across research centers and consortia, and appears in datasets produced by institutions such as the National Institutes of Health, the Wellcome Trust, and the European Molecular Biology Laboratory. ZDH has been investigated alongside proteins and pathways implicated in human physiology and disease by groups at Harvard Medical School, the Broad Institute, Stanford University, and the Sanger Institute.
ZDH denotes a specific gene product designated in locus annotation files and catalogues curated by databases such as UniProt, Ensembl, and NCBI Gene. Historical nomenclature surrounding ZDH has been subject to updates by the Human Genome Organisation Gene Nomenclature Committee and appears in genome assemblies produced by the Genome Reference Consortium. Alternative transcript names and protein isoforms have been catalogued in RefSeq and GENCODE releases. ZDH entries appear in genetic association reports from the International HapMap Project, the 1000 Genomes Project, and the Exome Aggregation Consortium.
Publications from the Max Planck Institute, Cold Spring Harbor Laboratory, and the American Society of Human Genetics reference ZDH when comparing orthologs from Mus musculus, Drosophila melanogaster, Danio rerio, and Caenorhabditis elegans. Cross-references in pathway resources such as KEGG, Reactome, and BioCarta link ZDH to metabolic and signaling modules annotated by the European Bioinformatics Institute and the Kyoto University Bioinformatics Center.
Functional studies have placed ZDH within cellular processes characterized by interactions with proteins and complexes studied at institutions including MIT, Johns Hopkins University, and Rockefeller University. ZDH has been profiled in proteomics analyses conducted by the Proteome Institute at the University of Toronto and in phosphoproteome screens led by laboratories at Oxford University and the Max Planck Society. Proteomic datasets from the Human Protein Atlas and PaxDb indicate tissue distribution patterns that overlap with proteins examined in cardiovascular research at the Cleveland Clinic, neurobiology research at Columbia University, and oncology research at Memorial Sloan Kettering Cancer Center.
Mechanistically, ZDH participates in biochemical cascades that intersect with signaling components such as kinases and ubiquitin ligases investigated at Yale University, the University of California San Francisco, and the Karolinska Institutet. Structural characterizations using cryo-electron microscopy and X-ray crystallography have been pursued in collaboration with facilities at the European Synchrotron Radiation Facility and the Advanced Photon Source, informing models associated with complexes described in studies from the Institute of Cancer Research and the Salk Institute.
Genetic variation in the ZDH locus has been reported in large-scale studies including genome-wide association studies from the Psychiatric Genomics Consortium, the CARDIoGRAM consortium, and the GIANT consortium. Variant annotation in ClinVar and the Human Gene Mutation Database has led to clinical case reports originating from tertiary centers such as Mayo Clinic, Massachusetts General Hospital, and Great Ormond Street Hospital. Certain alleles near ZDH co-segregate in pedigrees analyzed by teams at the University of Cambridge and Imperial College London, and have been included in meta-analyses by the Cochrane Collaboration and the World Health Organization collaborating centers.
Clinical phenotypes correlated with ZDH variants appear in cohorts characterized by collaborations among the European Genome-phenome Archive, the National Cancer Institute, and disease foundations such as the Michael J. Fox Foundation and the American Heart Association. Functional follow-up using model organisms has been conducted at EMBL, the Jackson Laboratory, and the European Mouse Mutant Archive to assess phenotypic consequences.
Detection of ZDH expression and variants employs assays developed and validated in diagnostic laboratories affiliated with laboratories at the Centers for Disease Control and Prevention, the Association for Molecular Pathology, and the College of American Pathologists. Techniques include targeted next-generation sequencing panels implemented by Foundation Medicine and Guardant Health, whole-exome sequencing pipelines used at Baylor Genetics and GeneDx, and RNA-seq workflows standardized by the Genomics England project. Protein-level detection has been achieved using immunohistochemistry protocols refined at the Memorial Sloan Kettering Cancer Center and mass spectrometry approaches established at the Max Planck Institute for Biochemistry.
Clinical-grade variant interpretation follows guidelines promulgated by the American College of Medical Genetics and Genomics and uses annotation resources from dbSNP, gnomAD, and the ClinGen Resource. Diagnostic reports integrating ZDH findings have been produced in multidisciplinary tumor boards at Stanford Cancer Institute, MD Anderson Cancer Center, and the Dana-Farber Cancer Institute.
Therapeutic strategies targeting pathways involving ZDH are under preclinical exploration at pharmaceutical companies such as Pfizer, Novartis, and AstraZeneca, and in biotech ventures incubated at JLABS and BioNTech. Small-molecule screens and biologic development have been carried out in collaboration with screening centers at the Broad Institute and the Scripps Research Institute. Clinical trial designs incorporating ZDH-related biomarkers are being considered by cooperative groups including the National Cancer Institute Experimental Therapeutics Clinical Trials Network and the European Organisation for Research and Treatment of Cancer.
Ongoing research directions involve systems biology approaches from the Institute for Systems Biology, single-cell analyses from the Chan Zuckerberg Biohub, and multi-omics integration led by consortia such as the Human Cell Atlas and the Cancer Genome Atlas. Future work aims to clarify interactions of ZDH with pathways studied at the Allen Institute for Brain Science and the Pasteur Institute, to prioritize targets for translational studies supported by the Bill & Melinda Gates Foundation and the Wellcome Trust.
Category:Proteins